BRPI0415187A - composição, método para matar bactérias, e, usos de composição e de bacteriófago - Google Patents

composição, método para matar bactérias, e, usos de composição e de bacteriófago

Info

Publication number
BRPI0415187A
BRPI0415187A BRPI0415187-9A BRPI0415187A BRPI0415187A BR PI0415187 A BRPI0415187 A BR PI0415187A BR PI0415187 A BRPI0415187 A BR PI0415187A BR PI0415187 A BRPI0415187 A BR PI0415187A
Authority
BR
Brazil
Prior art keywords
composition
bacteriophage
killing bacteria
vrsa
mrsa
Prior art date
Application number
BRPI0415187-9A
Other languages
English (en)
Inventor
Michael Wilson
Sean Nair
Original Assignee
Ucl Biomedica Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Biomedica Plc filed Critical Ucl Biomedica Plc
Publication of BRPI0415187A publication Critical patent/BRPI0415187A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

"COMPOSIçãO, MéTODO PARA MATAR BACTéRIAS, E, USOS DE COMPOSIçãO E DE BACTERIóFAGO". Uma composição compreendendo um conjugado de um fotossensibilizador e um bacteriófago é proporcionada. O conjugado pode ser usado para matar bactérias, particularmente MRSA, EMRSA, VRSA, hetero-VRSA ou CA-MRSA em um método selecionado de terapia fotodinâmica.
BRPI0415187-9A 2003-10-09 2004-10-08 composição, método para matar bactérias, e, usos de composição e de bacteriófago BRPI0415187A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0323699.9A GB0323699D0 (en) 2003-10-09 2003-10-09 Use of photosensitisation
PCT/GB2004/004305 WO2005034997A2 (en) 2003-10-09 2004-10-08 Conjugate of a photosensitiser and a bacteriophage

Publications (1)

Publication Number Publication Date
BRPI0415187A true BRPI0415187A (pt) 2006-11-28

Family

ID=29433608

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415187-9A BRPI0415187A (pt) 2003-10-09 2004-10-08 composição, método para matar bactérias, e, usos de composição e de bacteriófago

Country Status (12)

Country Link
US (1) US20070020241A1 (pt)
EP (1) EP1677826A2 (pt)
JP (1) JP5049010B2 (pt)
CN (1) CN1867357B (pt)
AU (1) AU2004280119B2 (pt)
BR (1) BRPI0415187A (pt)
CA (1) CA2541396C (pt)
GB (1) GB0323699D0 (pt)
IL (1) IL174759A0 (pt)
MX (1) MXPA06003975A (pt)
RU (1) RU2006115620A (pt)
WO (1) WO2005034997A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
GB201122158D0 (en) * 2011-12-22 2012-02-01 Ucl Business Plc Fluorescent composition
CN105579063A (zh) * 2013-06-05 2016-05-11 法尔哈德·哈菲泽 包括光活化活性组分的施用组合物的方法和具有给予药物组合物的方案的药物组合物
KR101623553B1 (ko) * 2013-07-23 2016-05-23 동성제약주식회사 여드름 치료, 예방 또는 개선에 유효한 클로린 e6
JP6269946B2 (ja) * 2014-03-25 2018-01-31 国立大学法人名古屋大学 細菌の増殖抑制
KR102251078B1 (ko) * 2014-10-28 2021-05-12 (주) 에이치엔에이파마켐 리조포스파티딜콜린과 클로린 e6의 결합체를 함유하는 여드름 치료용 리포좀 조성물
US10806788B2 (en) * 2018-01-23 2020-10-20 Purdue Research Foundation Chlorin-vitamin conjugates
CN110151994B (zh) * 2019-06-04 2021-07-27 中国科学院理化技术研究所 一种噬菌体及其在制备灭活细菌的光动力制剂中的应用
JP7247064B2 (ja) 2019-09-13 2023-03-28 株式会社東芝 電極、二次電池、電池パック、及び車両
WO2021146598A1 (en) * 2020-01-17 2021-07-22 Second Genome, Inc. Methods and compositions for treating atopic dermatitis
CN111529705A (zh) * 2020-04-28 2020-08-14 天津大学 噬菌体-CuNPs@MWCNTs的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2066552C1 (ru) * 1996-02-12 1996-09-20 Товарищество с ограниченной ответственностью "Био Прогресс" Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
DE69819360T2 (de) * 1997-11-20 2004-08-19 Cerus Corp., Concord Neue psoralene zur inaktivierung von pathogenen
WO2000061804A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AU2210402A (en) * 2000-11-29 2002-06-11 Norwegian Radium Hospital Res Photochemical internalization for virus-mediated molecule delivery into the cyosol
WO2003063902A2 (en) * 2002-02-01 2003-08-07 Gambro, Inc. Inactivation of west nile virus and plasmodium falciparum using alloxazine-derivating photosensitizers

Also Published As

Publication number Publication date
US20070020241A1 (en) 2007-01-25
EP1677826A2 (en) 2006-07-12
RU2006115620A (ru) 2007-11-27
GB0323699D0 (en) 2003-11-12
CA2541396C (en) 2012-12-11
CN1867357B (zh) 2012-05-16
IL174759A0 (en) 2006-08-20
WO2005034997A2 (en) 2005-04-21
JP5049010B2 (ja) 2012-10-17
MXPA06003975A (es) 2006-12-20
AU2004280119A1 (en) 2005-04-21
CA2541396A1 (en) 2005-04-21
WO2005034997A3 (en) 2005-12-08
CN1867357A (zh) 2006-11-22
AU2004280119B2 (en) 2010-02-25
JP2007508285A (ja) 2007-04-05

Similar Documents

Publication Publication Date Title
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
PT1420801E (pt) Utilização de fucanos no tratamento de adesões, artrite e psoríase
BRPI0416566A (pt) tratamento de fenilcetonúrias com bh4
ES2177084T3 (es) Uso de derivados de benzohidrilo sulfinilo para tratar la somnolencia de origen medicamentoso.
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
HK1075403A1 (en) Treatment of mastalgia with 4-hydroxy tamoxifen
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
ITRM20050514A1 (it) Olio ozonizzato, principio attivo di elevata stabilita' a base di perossidi utilizzabile per applicazioni terapeutiche mediche e per trattamenti domiciliari similari a quelli dell'ozonoterapia, senza l'utilizzo di ozono gassoso.
BRPI0415187A (pt) composição, método para matar bactérias, e, usos de composição e de bacteriófago
BR0312845A (pt) Tetratiomolibdato de tetrapropilamÈnio e compostos relacionados para terapias antiangiogênicas
BR0113644A (pt) Usos do inibidor de pde5 no tratamento de enxaqueca
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
SE9802208D0 (sv) Novel compounds
EP1074245A3 (en) Composition using mineral salts for therapeutic treatment
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
SE9802209D0 (sv) Novel compounds
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca
WO2005018569A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
ATE491457T1 (de) Kombinationstherapie gegen tumoren mit substituierten acryloyl-distamycin-derivaten, taxanen und/oder antimetaboliten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 41/00, 47/48; A61P 31/04

Ipc: A61K 41/00 (2011.01), A61K 47/48 (2011.01), A61P 3

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2327 DE 11-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 41/00 (2006.01), A61K 47/69 (2017.01), A61P 3